Jun. 18 at 4:30 AM
$TEM
Tempus AI and Whitehawk Therapeutics are partners, not the same company.
On October 16, 2025, the two companies announced a multi-year collaboration agreement focused on cancer drug development. Under the deal:
• Tempus provides its large AI-driven oncology database and analytics platform.
• Whitehawk uses Tempus' de-identified patient data to identify the best patient populations for clinical trials.
• The collaboration supports Whitehawk's antibody-drug conjugate (ADC) cancer programs targeting PTK7, MUC16, and SEZ6 proteins. �
